I cannot believe the events of the last 10 days aren't getting greater attention

Events which will live on infamy as a cautionary tale of western hubris, journalistic malpractice, and the problem of media proximity to power #Covid19

THREAD
On January 25, German media published claims (which they didn't check or verify) of a German government source that the AstraZeneca vaccine was only 8 percent effective among over 65s
A brief aside:

8 percent over 65s is relatively small as a sample size.

The Pfizer/BioNTech #Covid19 vaccine trial had more than 40 percent of participants over 55

But it's still hundreds of people, all of whom tolerated the vaccine well, and who saw robust antibody response
Later on the 25th, AstraZeneca responds to the "completely incorrect" German media reports:

"In November, we published data demonstrating that older adults showed strong immune responses to the vaccine, with 100% of older adults generating antibodies" https://www.rfi.fr/en/astrazeneca-rejects-incorrect-reports-on-covid-19-jab-efficacy-in-elderly
At this point, this non-story should have ended. The media in question was ethically (and I would argue legally) bound to issue a full correction

This whole sorry episode of non-specialists messing up their #Covid19 reporting ought to have been consigned to the scrapheap
Later that day, scientists, the UK prime minister and AstraZeneca itself defend the vaccine's efficacy/safety among over 65s, saying data from peer-reviewed phase 3 trials was "very reassuring" https://www.bbc.com/news/uk-55847387
January 29:

The EU's medicines agency officially recommends the AZ #Covid19 vaccine for "in people from 18 years of age"

So that's the EU's official drug agency endorsing the AZ vaccine as safe and effective for everyone, over 65s included https://news.yahoo.com/eu-regulator-backs-astrazeneca-vaccine-224558892.html
Now, as we've seen, AstraZeneca published peer-reviewed phase 3 results back in November showing "100 percent of older adults generating spike-specific antibodies after the second dose"

I'm no mathematician, but I don't think 100% is "quasi-ineffective" https://www.rfi.fr/en/astrazeneca-rejects-incorrect-reports-on-covid-19-jab-efficacy-in-elderly
At this point, it's worth taking a moment to look at the logistics of vaccination

Anyone who has ever had to organise mass vaccination campaigns will tell you that having the vaccine is the easy part. Getting it in to everyone's arm is the struggle
One key barrier to successful vaccination programmes is storage

As you know, Pfizer/BioNTech and Moderna's vaccines are mRNA vaccines. These need to be stored at ultra low temperatures (-80C/-20C) or else they perish
The AstraZeneca vaccine is a viral vector vaccine. While these require "growing" in factories they are far more robust than mRNA vaccines and don't require the same cold-chain

It can be kept for 6 months in the fridge. This is a godsend for distributors https://www.prevention.com/health/a35118263/astrazeneca-vs-pfizer-vs-moderna-covid-19-vaccine/
So this is a vaccine that is not only significantly easier to store than its competitors, it is nearly an order of magnitude cheaper

But I digress
So, to sum up:

What started out as a newspaper error has been allowed to escalate to a point where two rich European nations, whose citizens are dying in their 10,000s, end up denying their most vulnerable population a safe, cheap, easily-storable and effective #Covid19 vaccine
Epilogue:

None of this happened while we were still working out what #Covid19 is, how it transmits and kills, or what vaccines work well against it

This is a year into a pandemic in which governments vowed to move hell and high water to protect their populations
And I fear that voters in Western nations have been conditioned to believe that 10,000s of #Covid19 deaths were unavoidable, as if there was no country on Earth that could have done more to prevent such horror
You can follow @patrickgaley.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled:

By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.